Monthly Archives: September 2013
Biotechs and SMEs will be allocated 20% of the overall budget in the Horizon 2020 scheme
While the new 7-year funding scheme of EU, “Horizon 2020” will continue to fund excellent basic research (17% of the total budget), an effort is being made to attract small and medium enterprises (SMEs) to participate in research consortia. After a two-and-a-half-year negotiation, the European Council and the European Parliament reached an agreement (pending final sign-off) that SMEs will claim a 20% of the total budget in an act that aims to boost European economy.
Open access publication of results of all research funded under Horizon 2020 will be mandatory and awards will be made within 8 months as opposed to 12 months, which is the current scheme.
Industry – academia partnerships: way to go for anticancer drug development?
Industry – academia partnerships are increasingly growing in an effort to make the drug discovery process more efficient. In a Cancer Research UK perspective, several industrial collaborations are outlined with an eye on the distinct but com-plementary expertise brought about in anti-cancer drug development.
For more industry – academia initiatives check out
GlaxoSmithKline’s Discovery Fast Track competition for academic researchers
Eli Lilly’s Open Innovation Platform
Marie Curie’s Industry-Academia Partnerships and Pathways (IAPP)
Read another article on industry – academia partnerships from Science Magazine and an older article from this blog on the topic here.